A

argenx SE

D
ARGX
USD
2.01
(0.3414%)
Market Closed
6,234.00
Volume
-0.23816
EPS
-
Div Yield
-168.785710
P/E
35,324,648,274.75
Market Cap
Today
0.3414%
1 Week
0.761%
1 Month
12.892%
6 Months
48.132%
12 Months
18.796%
Year To Date
55.473%
All Time
0%
News

Argentina's Poverty Rate Surges as Austerity Bites Amid Economic Crisis

27.09.2024
Economy news

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
NVS
NVS
0.23
(0.2153%)
USD
REGN
REGN
8.505
(1.0417%)
USD
ABBV
ABBV
-0.78
(-0.3876%)
USD
BMY
BMY
-0.57
(-1.0313%)
USD
GSK
GSK
0.89
(2.4881%)
USD
SNY
SNY
-1.11
(-2.1003%)
USD
PFE
PFE
0.105
(0.3839%)
USD
LLY
LLY
21.245
(2.7359%)
USD

Title:
argenx SE

Sector:
Healthcare
Industry:
Biotechnology
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Do you need help or have a question?
Contact Us